Glycomet 250 mg (Metformin)

Product Overview

Glycomet 250 mg is a prescription oral antihyperglycemic agent for Type 2 diabetes mellitus. Produced by USV Pvt Ltd, each strip contains ten immediate‑release tablets delivering 250 mg of Metformin. Packs of 100, 200, or 300 tablets suit short‑term or long‑term regimens, with larger packs providing cost savings and fewer reorders. All packs are sealed and display the expiration date on the outer wrapper. Shipping takes six to fifteen days, depending on destination and courier, and shipments can be tracked online. The medication meets U.S. pharmaceutical standards and is manufactured under Good Manufacturing Practice (GMP) conditions.

What is Glycomet 250 mg

Glycomet belongs to the biguanide class of antidiabetic medications. Metformin, its active ingredient, lowers hepatic glucose production and improves peripheral insulin sensitivity. Unlike sulfonylureas, Glycomet does not stimulate insulin release, reducing hypoglycemia risk when used alone. The 250 mg dose is often chosen for initial therapy or patients transitioning from lower doses. Biguanides are among the oldest oral antidiabetic classes, dating to the 1950s, and are valued for their safety, lack of weight gain, and cardiovascular benefits, making them suitable for overweight and obese patients. Metformin improves insulin sensitivity without stimulating insulin secretion. Clinical guidelines recommend Metformin as first‑line therapy for most Type 2 diabetes patients, and Glycomet offers a reliable, cost‑effective option. For a comprehensive review of efficacy data, see the NIH compilation of Metformin studies.

Uses and Benefits

The primary therapeutic use of Glycomet 250 mg is to lower blood glucose in adults with Type 2 diabetes when lifestyle changes are insufficient. Clinical trials show it reduces HbA1c by 1.5 % to 2 % on average, lowers fasting glucose, and can cause modest weight loss. Studies also link Metformin to reduced cardiovascular events such as myocardial infarction, especially in patients with heart disease, and to a roughly 15 % relative risk reduction of major cardiovascular incidents. It may also modestly lower BMI and improve lipid profiles, including lower triglycerides and higher HDL cholesterol. Off‑label, it is sometimes used for polycystic ovary syndrome (PCOS) under medical supervision to aid ovulation. For a comprehensive review of efficacy data, see the NIH compilation of Metformin studies.

How It Works

Metformin exerts its glucose‑lowering effect through several interconnected mechanisms. First, it inhibits hepatic gluconeogenesis, thereby reducing the liver’s output of glucose. Second, it enhances insulin‑stimulated glucose uptake in skeletal muscle and adipose tissue by increasing the translocation of GLUT‑4 transporters to the cell membrane. Third, Metformin slows intestinal absorption of carbohydrates and modestly increases peripheral glucose utilization. These actions collectively decrease circulating glucose concentrations without provoking excessive insulin release, which explains the low risk of hypoglycemia. Pharmacokinetic studies indicate that Metformin is transported into hepatic cells via the organic cation transporter 1 (OCT1), where it exerts its intracellular effects. In addition to hepatic and peripheral actions, Metformin modulates the gut microbiome, reducing intestinal absorption of glucose and influencing entero‑endocrine signals that affect satiety. The drug also inhibits hepatic gluconeogenesis by down‑regulating key enzymes such as glucose‑6‑phosphatase, further decreasing hepatic glucose output. Detailed mechanistic insights are available from the NIH mechanistic overview.

Dosage Guidelines

Typical initiation of therapy consists of one Glycomet 250 mg tablet taken with the morning meal, followed by a second tablet with the evening meal if additional glycemic control is needed. Dose titration may increase the daily dose to 500 mg twice daily or 850 mg twice daily, depending on the patient’s response and tolerability. For patients with impaired renal function, the daily dose should be reduced: a maximum of 500 mg per day is recommended when the estimated glomerular filtration rate (eGFR) is between 30–45 mL/min/1.73 m², and the drug is generally avoided when eGFR falls below 30 mL/min/1.73 m². Patients undergoing dialysis may require further dose adjustments. Therapeutic dose adjustments are typically guided by serial measurements of HbA1c; a reduction of 1 % to 1.5 % is often observed after three months of stable dosing at 500 mg twice daily. In pediatric patients aged 10 years and older, Metformin is approved as an adjunct to diet and exercise for the treatment of Type 2 diabetes, with dosing similar to adults. It is essential to swallow the tablet whole with adequate fluid and to avoid abrupt discontinuation without medical supervision. More detailed dosing recommendations are outlined in the FDA prescribing label.

Side Effects

Most adverse reactions to Glycomet are mild and limited to the gastrointestinal tract, such as nausea, diarrhea, abdominal cramping, and a transient metallic taste, which often improve after the first one to two weeks or with dose titration. Rare but serious adverse events include lactic acidosis, a potentially fatal condition marked by muscle pain, rapid breathing, profound fatigue, and abdominal discomfort; seek immediate medical attention if these symptoms occur. Chronic Metformin therapy can lower serum vitamin B12 levels; periodic supplementation or dietary counseling may be needed, especially in patients with malabsorption. Very rare cases of hepatic enzyme elevation have been reported; routine liver function tests are advised at baseline and periodically. Management may involve dose reduction, taking the medication with food, or switching to an extended‑release formulation.

Warnings and Precautions

Glycomet is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and known hypersensitivity to Metformin. Caution is advised in elderly patients, those with liver disease, and individuals undergoing procedures that use iodinated contrast, due to an increased risk of lactic acidosis. Limit alcohol intake and avoid excessive carbohydrate consumption that may worsen glycemic control. Pregnant or breastfeeding women should consult a clinician before use. Discontinue Metformin before intravascular contrast imaging to prevent lactic acidosis related to reduced renal perfusion. Interactions with drugs such as trimethoprim‑sulfamethoxazole, cimetidine, or other cationic agents may affect clearance; monitoring is recommended. For full safety details, see the MedlinePlus entry on Metformin.

Storage and Handling

Store Glycomet tablets at room temperature, away from moisture, heat, and direct sunlight. Keep the strip sealed until use and discard any tablets that are discolored, cracked, or expired. The expiration date is on the wrapper and should be checked before use. Keep the medication out of reach of children and pets, and avoid storing it in humid areas such as bathrooms.

Patient Counseling

Patients should take Glycomet exactly as prescribed, usually with meals to reduce gastrointestinal upset. Regular monitoring of blood glucose and reporting of persistent side effects to the clinician are essential. Laboratory tests, including renal function (eGFR) and periodic vitamin B12 levels, should be performed as advised. Adherence to the dosing schedule is critical to maintain glycemic control. Patients are encouraged to adopt a balanced diet low in refined carbohydrates and regular physical activity to enhance Metformin’s benefits. If a surgical procedure involving contrast dye is planned, the provider may advise temporarily discontinuing Metformin for 48 hours before and after to reduce lactic acidosis risk.

Frequently Asked Questions

What condition does Glycomet 250 mg treat?

Glycomet 250 mg is indicated for the management of Type 2 diabetes mellitus, helping to lower blood glucose levels when diet and exercise alone are insufficient.

How should I store Glycomet tablets?

Store the medication at room temperature, away from moisture and heat. Keep the strip sealed until ready to use, and discard any tablets that become discolored or damaged.

Can Glycomet be taken with other diabetes medications?

Yes, Glycomet is often combined with other oral hypoglycemics or insulin therapy, but dosage adjustments may be necessary to prevent hypoglycemia; always follow your physician’s guidance.

Is Glycomet safe for patients with kidney disease?

Glycomet should be used with caution in patients with impaired renal function; dose reduction or avoidance is recommended when the estimated glomerular filtration rate falls below 30 mL/min/1.73 m².

Where can I find more detailed prescribing information?

Refer to the official FDA label, the USV product insert, or reputable medical resources such as MedlinePlus and the National Institutes of Health (NIH) for comprehensive guidance.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)